Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease

Launched by VANDERBILT UNIVERSITY MEDICAL CENTER · Aug 7, 2025

Keywords

ClinConnect Summary

This study is looking at patients with inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, who are switching from receiving a medicine called vedolizumab through an IV (a needle in the vein) to getting it as a shot under the skin, known as subcutaneous (SC) administration. The researchers want to understand how patients are being dosed with this new method and how well they do after making the switch. This information will come from reviewing medical records of patients who start the shot form of vedolizumab as part of their regular care between September 2023 and December 2024.

To be part of this study, patients need to be 18 years or older, have Crohn’s disease or ulcerative colitis, and have been referred by a specific healthcare provider at Vanderbilt University Medical Center (VUMC) to start the shot form of vedolizumab. Patients who get the medicine from outside providers or who stop treatment or change doctors before starting the shot won’t be included. Since this study looks back at existing medical records, participants won’t need to change their treatment or do anything extra—they will simply have their health information reviewed to help doctors learn more about this new way of giving vedolizumab.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with Crohn's Disease or Ulcerative Colitis referred to start SC vedolizumab from a VUMC IBD provider and receive at least 1 dose of subcutaneous vedolizumab
• • Age 18 years old or older
• Exclusion Criteria:
• • Patients prescribed SC vedolizumab from a non-VUMC provider
• • Patients lost to follow-up or change in provider or medication before SC formulation started